A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI).